Sustainable Solutions to Achieve Therapeutic Goals for Patients with Myelofibrosis
| Overview / Abstract: |
When it comes to treating your patients with myelofibrosis (MF), are you applying the latest guidance in practice? Evidence shows that it takes an average of 17 years for evidence to change practice but how can we incorporate treatment advances to improve patient outcomes today? This activity looks to bridge the chasm between education and implementation by framing available evidence and guideline recommendations for MF, including diagnosis, risk stratification, JAK inhibition, monitoring response to therapy, and patient education strategies, into routine clinical practices that can be easily adapted by practices of varying size and resources. Through this activity, learners are provided the resources and tools needed to optimize risk and symptom assessment, as well as treatment selection, for patients with myelofibrosis. |
|
Expiration |
Oct 27, 2024 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.0 AMA PRA Category 1 Credit™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Brady Stein, MD, MHS |
|
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from CTI BioPharma Corp. |
|
Keywords / Search Terms |
ACHL CME, CE, CTI Biopharma, Brady Stein, myelofibrosis, myeloproliferative, MF, risk assessment, neoplasm, coring system, community, academic, treatment selection, therapy selection, patient risk, evidence-based, rare, rarity, quality of life Free CE CME |
|